Collectively, our findings demonstrate that CDC6/THBS1/AKT signaling drives glycolysis and accelerates pancreatic cancer progression, suggesting that the CDC6/THBS1/AKT axis may serve as a promising therapeutic target for pancreatic cancer. This evidence concerns the gene AKT1 and pancreatic neoplasm.